content: <PAGE>
  
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
                  Date of Report (Date of earliest event reported):
                        January 23, 2002 (January 22, 2002)
  
                               COR THERAPEUTICS, INC.
               (Exact name of registrant as specified in its charter)
  
         Delaware                0-19290                   94-3060271
  (State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
  
                                256 East Grand Avenue
                        South San Francisco, California 94080
                (Address of principal executive offices and zip code)
  
         Registrant's telephone number, including area code: (650) 244-6800
  
  
  
  
                                         1.
  
  <PAGE>
  
  Item 5.       Other Events.
  
       On January 22, 2002, COR Therapeutics, Inc. announced financial results for
  the fourth fiscal quarter and year ended December 31, 2001. A copy of the press
  release entitled "Strong Sales of Integrilin(R) (eptifibatide) Injection Account
  for Profitable Fourth Quarter and Year End 2001 for COR Therapeutics, Inc."
  concerning the announcement is filed herewith as Exhibit 99.1.
  
  Item 7.       Financial Statements, Pro Forma Financial Information
                and Exhibits.
  
  (c)           Exhibits
  
  Exhibit 99.1  Press Release, dated January 22, 2002, entitled "Strong Sales of
                Integrilin(R) (eptifibatide) Injection Account for Profitable
                Fourth Quarter and Year End 2001 for COR Therapeutics, Inc."
  
                                         2.
  
  <PAGE>
  
                                     SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                          COR THERAPEUTICS, INC.
  
  Dated: January 23, 2002                 By: /s/ Patrick A. Broderick
                                              ------------------------------------
                                              Patrick A. Broderick
                                              Senior Vice President
                                                and General Counsel
  
  
                                         3.
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "d8k.txt", "description": "FORM 8-K", "secsgml_size_bytes": 2543}]
metadata_filer: {"company-data": {"conformed-name": "COR THERAPEUTICS INC / DE", "cik": "0000874865", "assigned-sic": "2834", "irs-number": "943060271", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-19290", "film-number": "02515056"}, "business-address": {"street1": "256 E GRAND AVE STE 80", "city": "SOUTH SAN FRANCISCO", "state": "CA", "zip": "94080", "phone": "4152446800"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
                       Pursuant to Section 13 or 15(d) of the
                           Securities Exchange Act of 1934
  
                  Date of Report (Date of earliest event reported):
                        January 23, 2002 (January 22, 2002)
  
                               COR THERAPEUTICS, INC.
               (Exact name of registrant as specified in its charter)
  
         Delaware                0-19290                   94-3060271
  (State of jurisdiction) (Commission File No.) (IRS Employer Identification No.)
  
                                256 East Grand Avenue
                        South San Francisco, California 94080
                (Address of principal executive offices and zip code)
  
         Registrant's telephone number, including area code: (650) 244-6800
  
                                         1.
  Item 5.       Other Events.
  
       On January 22, 2002, COR Therapeutics, Inc. announced financial results for
  the fourth fiscal quarter and year ended December 31, 2001. A copy of the press
  release entitled "Strong Sales of Integrilin(R) (eptifibatide) Injection Account
  for Profitable Fourth Quarter and Year End 2001 for COR Therapeutics, Inc."
  concerning the announcement is filed herewith as Exhibit 99.1.
  
  Item 7.       Financial Statements, Pro Forma Financial Information
                and Exhibits.
  
  (c)           Exhibits
  
  Exhibit 99.1  Press Release, dated January 22, 2002, entitled "Strong Sales of
                Integrilin(R) (eptifibatide) Injection Account for Profitable
                Fourth Quarter and Year End 2001 for COR Therapeutics, Inc."
  
                                         2.
  SIGNATURES
  
       Pursuant to the requirements of the Securities Exchange Act of 1934, the
  Registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
                                          COR THERAPEUTICS, INC.
  
  Dated: January 23, 2002                 By: /s/ Patrick A. Broderick
                                              ------------------------------------
                                              Patrick A. Broderick
                                              Senior Vice President
                                                and General Counsel
  
                                         3.